Skip to Main Content

Amid a firestorm of controversy around its decision to charge $56,000 a year for an Alzheimer’s disease treatment whose benefits are disputed, Biogen defended its decision on Tuesday, pointing to lifesaving cancer therapies that can cost nearly three times as much.

“We believe the price is substantiated by the value it is expected to bring to patients, caregivers, and society,” CEO Michel Vounatsos said on a triumphant conference call with Wall Street analysts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment